FONDITA

Fondita Healthcare

Share Class B (accumulating)

As of 30 June 2026

SFDR Article 8

Fund Description

Fondita Healthcare is a global, actively managed equity fund that invests in companies which improve health and well-being. The fund has a sustainable investment objective with a particular focus on social responsibility. The fund invests in companies which promote current and unmet medical needs and improve access to medicine and medical care. This is achieved by investing in companies active in the innovation, production and distribution of pharmaceuticals and healthcare equipment, tools and supplies, as well as diagnostic and healthcare services. Operationally, the companies act responsibly with a focus on social sustainability aspects such as improved diversity and gender equality and with environmental goals such as CO2 neutrality. The investment philosophy favors quality companies with good growth prospects in the different sub-sectors of healthcare. The Fund is classified as an Article 9 fund (SFDR) and has social sustainability as an investment objective. The fund consists of a concentrated portfolio of global holdings with no market-cap restrictions.

Janna Haahtela

Marcus Björkstén

Fund Performance



Fondita Healthcare B

MSCI World Health Care Net Eur Index

The fund has no official benchmark.

Fund Performance

Rolling (12 months)	30.06.2021 - 30.06.2022	30.06.2022 - 30.06.2023	30.06.2023 - 28.06.2024	28.06.2024 - 30.06.2025	30.06.2025 - 30.06.2026
Fondita Healthcare	-17.96%	4.26%	11.74%	-12.17%	2.81%
Per Calendar Year	2021	2022	2023	2024	2025
Fondita Healthcare	29.83%	-27.57%	7.92%	9.10%	-4.25%

Monthly Comment

Global equity markets delivered mixed performance in June. The first half of the month was characterized by geopolitical uncertainty, rising oil prices and renewed inflation concerns, which weighed on investor risk appetite. The technology sector, particularly semiconductor stocks, experienced elevated volatility as both valuations and growth expectations came under scrutiny. Market sentiment improved during the latter part of the month as geopolitical tensions eased. European equities outperformed their U.S. counterparts despite the ECB's interest rate cut, with defensive sectors leading the gains. Fondita Healthcare advanced 3.36% in June, while the global healthcare index returned 7.37%. Large U.S. pharmaceutical companies were among the main beneficiaries of the ongoing sector rotation. Relative performance was negatively affected by holdings in Boston Scientific, Siegfried and Onward Medical. Boston Scientific and Siegfried came under pressure following analyst downgrades during the month, while Onward Medical was impacted by weaker investor appetite for smaller-cap companies. The strongest contributors to fund performance were Straumann, Eli Lilly and Merck & Co. Straumann rose sharply after raising its 2026 earnings guidance, citing a recovery in China and lower tariff-related costs. Eli Lilly reached several new record highs during June following the announcement of expanded Medicare coverage and sector rotation. Merck & Co delivered a number of regulatory successes, which were well received by the market. (30.6.2026)

Key Data

	1M	3M	6M	YTD	1Y	3Y	5Y	10Y	Inception
Return	3.36%	4.59%	-4.41%	-4.41%	2.81%	0.90%	-13.70%		39.83%
Return p.a.					2.81%	0.30%	-2.90%		4.26%
Std Dev	16.79%	15.23%	14.63%	14.63%	13.68%	12.68%	14.76%		15.19%
Sharpe Ratio	2.68	1.20	-0.75	-0.75	0.05	-0.21	-0.34		0.21
Sortino Ratio	5.27	1.96	-1.11	-1.11	0.08	-0.29	-0.46		0.28
Beta	0.81	0.83	0.84	0.84	0.83	0.81	0.66		0.48
Max Drawdown	-2.65%	-5.91%	-13.85%	-13.85%	-13.85%	-21.28%	-30.25%		-30.50%

Key Facts

ISIN	FI4000321096
WKN	A2PNY0
NAV	139.8324 EUR
Fund Size	13.05 M. EUR
Fund Currency	EUR
Share Class Currency	EUR
Fund Domicile	Finland
Registered for Distribution	FIN, SWE, NOR, GER, AUT
Legal Form	UCITS
Fund Category	Healthcare Global All Cap
Inception Date Fund	14.06.2018
Inception Date Share Class	14.06.2018
Business Year	01.01.-31.12
Minimum Investment	None
Minimum Follow-up Investment	None
Investment Horizon	Long, 7 years
Initial Issue Price	100 EUR
SRI	4
Pricing Frequency	daily
Order Acceptance Deadline (cut-off)	13:30 CET
Ongoing charges (TER)	2.00%
Subscription Fee	0.00%
Redemption Fee	0.00%
Performance Fee	0.00%

No subscription fee is charged by the fund management company. A distribution fee of maximum 5,00 % may be applied at the time of purchase through a financial intermediary. The distributor selling you the product will inform you of the actual charge. More detailed information about charges/fees and other information is available in the fund prospectus, at www.fondita.com.

Risk Profile (SRI)

1	2	3	**4**	5	6	7

lower risk, typically lower return

higher risk, typically higher return

ESG-Data

Classification according to Disclosure Regulation (Regulation (EU) 2019/2088)	SFDR Article 8
MSCI ESG-Rating (scope 1+2)	A
CO_2-Intensity	7.0 t CO_2e/$M Sales

Source: MSCI

FONDITA

Fondita Healthcare

Share Class B (accumulating)

SFDR Article 8

As of 30 June 2026

Healthcare sub-sectors



Pharma	66.3%
Equipment	32.3%
Cash	1.4%

Currency Allocation



USD	44.4%
EUR	15.6%
CHF	14.0%
SEK	12.6%
DKK	11.5%
GBP	1.9%

Sales

Fredrik von Knorring
Fondita Fund Management Company Ltd.
Aleksanterinkatu 48 A
00100 Helsinki
Finland
Phone: +358 9 66 89 89 33
Mobile: +358 40 828 5251
fredrik.von.knorring@fondita.fi
fondita.com

Country Allocation



USA	44.4%
Switzerland	14.0%
Sweden	12.6%
Denmark	11.5%
Belgium	6.7%
Germany	3.5%
Others	7.3%

Market Cap



> 10 Bn. EUR	72.4%
4 - 10 Bn. EUR	5.3%
800 M. EUR - 4 Bn. EUR	15.2%
< 800 M. EUR	5.7%
Cash	1.4%

Allocations as of 30.06.2026

Top Positions

Eli Lilly & Co	Pharma	9.76%
Merck & Co	Pharma	6.39%
AstraZeneca	Pharma	5.93%
Novo Nordisk	Pharma	4.84%
Novartis	Pharma	4.73%
Unitedhealth Group	Equipment	4.47%
Danaher	Pharma	3.97%
Argenx	Pharma	3.73%
Straumann	Equipment	3.54%
Sartorius	Pharma	3.52%

Disclaimer

The past performance of the investment fund does not provide any guarantee of future results. Depending on market conditions, the fund unit value may rise or fall. The future performance of the fund depends on the development of the markets and the Fund Manager's success with the chosen investments. The fund is euro denominated. Thereby changes in currency values may affect the value of the investments. The fund is not covered by the Deposit Guarantee Fund nor the Investor's Compensation Fund. The fund prospectus and KID are available on our website www.fondita.com.